Highlights AstraZeneca Pharma India Limited

Equities

ASTRAZEN

INE203A01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:46 06/03/2026 pm IST			5-day change	1st Jan Change
8,740.10 ^INR	+1.67%		-1.16%	-3.00%

11/02	AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
11/02	AstraZeneca Pharma India Dec-quarter PAT 325.9 million rupees	RE

Highlights

11/02	AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
11/02	AstraZeneca Pharma India Dec-quarter PAT 325.9 million rupees	RE
11/02	Astrazeneca Pharma India Limited Appoints Tanya Sanish as Company Secretary and Compliance Officer, Effective February 23, 2026	CI
11/02	Diary - India economic, corporate events on February 11	RE
10/02	Indian Markets Extend Gains for Third Session On Tuesday Amid Positive Global Cues	MT
10/02	AstraZeneca Pharma India Gets Regulatory Nod to Import, Sell Cancer Drug	MT
17/12	Astrazeneca Pharma India receives permission to import datopotamab deruxtecan powder to India	RE
17/11	AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited Announce Partnership to Help Patients Living with Hyperkalaemia in India	CI
08/11	AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
07/11	Astrazeneca Pharma India Sept-quarter PAT 542.2 million rupees	RE
18/25/18	Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer	CI
18/25/18	Amgen and AstraZeneca Announce FDA Approves TEZSPIRE®? for Chronic Rhinosinusitis with Nasal Polyps	CI
12/25/12	AstraZeneca Pharma India Limited Receives a Show Cause Notice from National Pharmaceutical Pricing Authority	CI
18/25/18	Astrazeneca Pharma India Limited Approves Declaration for Financial Year 2024-25	CI
14/25/14	AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
14/25/14	Astrazeneca Pharma India June-quarter pat 558.3 million rupees	RE
18/25/18	For final dividend	FA
30/25/30	AstraZeneca Pharma India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI
30/25/30	Astrazeneca Pharma India March-Quarter PAT 582.5 Million Rupees	RE
30/25/30	Astrazeneca Pharma India Dividend Of 32 Rupees Per Share	RE
30/25/30	AstraZeneca Pharma India Limited announces Annual dividend, payable on September 12, 2025	CI
15/25/15	Astrazeneca Pharma India Surrenders Marketing Authorisation For Olaparib Tablets	RE
06/25/06	Astrazeneca Pharma India Limited Receives Permission from Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India	CI
28/25/28	Astrazeneca Pharma India Receives Permission To Import Durvalumab For Additional Indication	RE
28/25/28	AstraZeneca Pharma India Limited Receives Approval for Additional Indication of Durvalumab Solution	CI